Robert S Hogg

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program
    Christopher G Au-Yeung
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    BMC Public Health 10:642. 2010
  2. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  3. ncbi Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020
    Aranka Anema
    British Columbia Centre for Excellence in HIV AIDS, St, Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS Res Ther 8:13. 2011
  4. ncbi CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  5. ncbi Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    Robert S Hogg
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS Med 3:e356. 2006
  6. ncbi HIV/AIDS in Vancouver, British Columbia: a growing epidemic
    Colin W McInnes
    British Columbia Centre for Excellence in HIV AIDS, St, Paul s Hospital, 608 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada
    Harm Reduct J 6:5. 2009
  7. ncbi Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy
    Magdalena A Recsky
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
    J Infect Dis 190:285-92. 2004
  8. ncbi Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy
    Anita Palepu
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, University of British Columbia, BC, Canada
    Drug Alcohol Depend 84:188-94. 2006
  9. ncbi Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings
    Richard Bedell
    Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    Antivir Ther 8:379-84. 2003
  10. ncbi Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005

Detail Information

Publications87

  1. ncbi Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program
    Christopher G Au-Yeung
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    BMC Public Health 10:642. 2010
    ..We examined the rate of underreporting of deaths by manual methods as compared with electronic reports from a vital event registry...
  2. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  3. ncbi Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020
    Aranka Anema
    British Columbia Centre for Excellence in HIV AIDS, St, Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS Res Ther 8:13. 2011
    ..abstract:..
  4. ncbi CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  5. ncbi Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    Robert S Hogg
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS Med 3:e356. 2006
    ..The objective of this study was to determine the impact of the emergence of drug-resistance mutations on survival among persons initiating HAART...
  6. ncbi HIV/AIDS in Vancouver, British Columbia: a growing epidemic
    Colin W McInnes
    British Columbia Centre for Excellence in HIV AIDS, St, Paul s Hospital, 608 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada
    Harm Reduct J 6:5. 2009
    ..These results suggest that HIV infection is having a relatively large impact in Vancouver and that evidence-based prevention and harm reduction strategies should be expanded...
  7. ncbi Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy
    Magdalena A Recsky
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
    J Infect Dis 190:285-92. 2004
    ..001). CONCLUSION: Only a relatively low prevalence of multidrug resistance was observed in this cohort, indicating that the exhaustion of treatment options because of drug resistance was not a significant contributor to mortality...
  8. ncbi Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy
    Anita Palepu
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, University of British Columbia, BC, Canada
    Drug Alcohol Depend 84:188-94. 2006
    ..We examined the association of methadone maintenance therapy (MMT) with highly active antiretroviral therapy (HAART) adherence and HIV treatment outcomes among a cohort of HIV/HCV co-infected injection drug users (IDUs)...
  9. ncbi Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings
    Richard Bedell
    Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    Antivir Ther 8:379-84. 2003
    ..Our results suggest that, if appropriately validated, judicious application of total lymphocyte counts could overcome one of the practical obstacles to more widespread provision of antiretroviral therapy in resource-poor settings...
  10. ncbi Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005
    ....
  11. ncbi Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, British Columbia, Canada
    Antivir Ther 8:91-6. 2003
    ..1). The data suggest that HIV p6Gag insertions are not exclusively related to drug resistance and may not influence response to antiretroviral therapy, but may be linked to sequence variations in the HIV envelope...
  12. ncbi Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, British Columbia, Canada
    J Infect Dis 198:59-67. 2008
    ..These results provide powerful additional motivation to accelerate the roll out of HAART programs aggressively targeting those in medical need, both for their own benefit and as a means of decreasing new HIV infections...
  13. ncbi Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection
    Vikram S Gill
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Clin Infect Dis 50:98-105. 2010
    ....
  14. ncbi Sexual violence among two populations of men at high risk of HIV infection
    Paula Braitstein
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS Care 18:681-9. 2006
    ..Sexual violence is differentially associated with different health risk behaviors, depending on the age at first occurrence and the primary HIV risk factor (i.e. MSM vs. IDU)...
  15. ncbi Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy
    Anita Palepu
    All the authors are with the University of British Columbia, British Columbia, Canada
    J Urban Health 80:667-75. 2003
    ..As well, increased outreach to HIV-infected drug users recently released from prison to ensure continuity of care needs to be further developed...
  16. ncbi Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy
    Viviane D Lima
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 21:685-92. 2007
    ..To characterize the temporal changes in mortality and life expectancy among HIV-positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to 2004...
  17. ncbi Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence
    Thomas M Lampinen
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    BMC Public Health 7:35. 2007
    ..However, few studies in recent years have characterized use. From 1999 to 2004, new HIV diagnoses among MSM in British Columbia increased 78%, prompting us to examine the prevalence and correlates of this modifiable HIV risk factor...
  18. ncbi Differential impact of adherence on long-term treatment response among naive HIV-infected individuals
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 22:2371-80. 2008
    ....
  19. ncbi Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy
    Zabrina L Brumme
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    J Infect Dis 195:1694-704. 2007
    ....
  20. ncbi Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS 17:711-20. 2003
    ..We evaluated whether non-immune-based factors such as physician experience and adherence could affect survival among HIV-infected adults starting HAART...
  21. ncbi Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, and Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Infect Dis 188:1421-5. 2003
    ..71; 95% confidence interval, 1.08-2.70; P=.023). If appropriately confirmed, these findings have important implications for the development of therapeutic guidelines...
  22. ncbi Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
    Paula Braitstein
    British Columbia Center for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    AIDS 20:323-31. 2006
    ..To characterize the impact of hepatitis C (HCV) serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART...
  23. ncbi Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl
    Evan Wood
    British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, 667-1081 Burrard Street, Vancouver, BC, Canada
    AIDS 20:1117-23. 2006
    ..89-1.65; P = 0.232). CONCLUSION: HIV RNA > or = 100 000 copies/ml was only associated with mortality among HIV-infected patients initiating HAART with CD4 cell counts > or= 200 cells/microl if the patients were non-adherent...
  24. ncbi Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 188:1164-70. 2003
    ..5%) received antiretroviral medication >or=75% of the time during their first year receiving therapy. The data demonstrate the need for novel interventions to expand HIV care to specific populations...
  25. ncbi Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy
    David M Moore
    British Columbia Centre for Excellence in HIV AIDS, 608 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
    J Acquir Immune Defic Syndr 40:288-93. 2005
    ..To examine the independent association of discordant virologic and immunologic responses to highly active antiretroviral therapy (HAART) with mortality...
  26. ncbi Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 608 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Subst Use Misuse 40:1153-67. 2005
    ..These findings demonstrate low levels of addiction treatment among Vancouver IDUs and suggest that programs may need to be targeted towards specific populations with poor access...
  27. ncbi Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    BMJ 338:b1649. 2009
    ..To examine the relation between plasma HIV-1 RNA concentrations in the community and HIV incidence among injecting drug users...
  28. ncbi CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals
    Andrew J Low
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS Res Hum Retroviruses 24:219-28. 2008
    ..The ability to predict X4 virus using genotypic determinants at positions 25 and 6-8 of the V3 loop is CD4 dependent, while position 11 appears to be CD4 independent...
  29. ncbi Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs
    Laura M Kuyper
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, and Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    Subst Use Misuse 41:883-99. 2006
    ..Syringe buyers were more likely to need help injecting, have difficulty finding new syringes, have binged on drugs, and have visited the SEP at least once weekly. Syringe buying most frequently occurred when the SEP was closed...
  30. ncbi Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC
    CMAJ 169:656-61. 2003
    ..We evaluated virological responses to HAART among HIV-1 infected patients who were injection drug users (IDUs) in a population-based setting where HIV/AIDS care is delivered free of charge...
  31. ncbi The impact of adherence on CD4 cell count responses among HIV-infected patients
    Evan Wood
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
    J Acquir Immune Defic Syndr 35:261-8. 2004
    ..85, 95% CI: 3.15-7.47). CONCLUSIONS: These data demonstrate that substantial CD4 gains are possible among highly advanced adherent patients and should contribute to the ongoing debate over the optimal time to initiate HAART...
  32. ncbi Factors predictive of 30-day postoperative mortality in HIV/AIDS patients in the era of highly active antiretroviral therapy
    Sam M Wiseman
    Department of Surgery, St Paul s Hospital and Faculty of Medicine, University of British Columbia, Vancouver, Canada
    Ann Surg 256:170-6. 2012
    ..Factors that predict HIV (human immunodeficiency virus)/AIDS patient postoperative mortality have remained poorly defined...
  33. ncbi Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies
    Evan Wood
    BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada
    AIDS 17:2629-34. 2003
    ..As such, it is likely that similar selection factors may explain why our findings contrast with several non-randomized studies showing worse clinical outcomes of patients prescribed nevirapine...
  34. ncbi Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen
    Zabrina L Brumme
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Antivir Ther 10:849-53. 2005
    ..Here we investigate associations between CCR5delta32 and HAART outcomes in a large, population-based cohort of >1000 antiretroviral-naive individuals initiating triple therapy over a median >5 year follow-up...
  35. ncbi Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response
    David M Moore
    BC Centre for Excellence in HIV AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    AIDS 20:371-7. 2006
    ..To determine if immunological response is associated with disease progression in patients with virological suppression after initiating HAART...
  36. ncbi Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings
    David M Moore
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 43:436-9. 2006
    ..The performance of immunologic monitoring for this purpose has not been evaluated, however...
  37. ncbi Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
    ..We aimed to estimate the association between plasma HIV-1 viral load, HAART coverage, and number of new cases of HIV in the population of a Canadian province...
  38. ncbi The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 608 1081 Burrard Street, Vancouver, British Columbia, Canada
    AIDS 21:1175-83. 2007
    ..To determine the impact of depressive symptoms on mortality among HIV/AIDS patients first initiating HAART and the potential role of patient adherence as a confounder and effect modifier in this association...
  39. ncbi Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    J Infect 52:233-6. 2006
    ..We examined the time to antiretroviral therapy (ART) use among antiretroviral naïve HIV infected injection drug users participating in a prospective cohort study in Vancouver, Canada...
  40. ncbi Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use
    Evan Wood
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    AIDS 19:1189-95. 2005
    ..These findings should help to allay fears that prescribing HAART to IDUs may result in elevated rates of resistance...
  41. ncbi Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort
    Laura M Kuyper
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 37:1470-6. 2004
    ....
  42. ncbi Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, and Faculty of Medicine, University of British Columbia, Canada
    J Infect Dis 192:466-74. 2005
    ....
  43. ncbi Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 188:541-8. 2003
    ..01). These results may reflect incomplete adherence, since a strong association (P<.001) was found between low drug levels and an imperfect prescription-refill record (<95%)...
  44. ncbi 'It's like the treasure': beliefs associated with semen among young HIV-positive and HIV-negative gay men
    Arn J Schilder
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    Cult Health Sex 10:667-79. 2008
    ..As such, these narratives are of direct importance to primary and secondary HIV prevention, including condom promotion and the development of rectal microbicides...
  45. ncbi Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes
    Anita Palepu
    Centre for Health Evaluation and Outcome Sciences, St Paul s Hospital, University of British Columbia, BC, Canada
    Antivir Ther 9:713-9. 2004
    ..To examine the effect of incarceration within 12 months of initiating highly active antiretroviral therapy (HAART) on non-adherence and HIV-1 RNA suppression...
  46. ncbi Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response
    Zabrina L Brumme
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS 17:201-8. 2003
    ....
  47. ncbi Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients
    Elizabeth Phillips
    British Columbia Centre for Excellence in HIV AIDS, Providence Healthcare, St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC, Canada
    AIDS 21:1561-8. 2007
    ....
  48. ncbi Sexual violence among a cohort of injection drug users
    Paula Braitstein
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
    Soc Sci Med 57:561-9. 2003
    ..Nevertheless, women and men are affected differently by sexual violence at different ages, and this has significant implications for health promotion programs, and specifically HIV prevention...
  49. ncbi Requiring help injecting independently predicts incident HIV infection among injection drug users
    Thomas Kerr
    British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, St. Paul's Hospital, Vancouver, Canada
    J Acquir Immune Defic Syndr 40:83-8. 2005
    ..79, 95% CI: 1.23-2.62) remained independent predictors of HIV seroconversion. CONCLUSIONS: These data demonstrate the need for interventions to reduce the risk of HIV infection among IDUs who require help injecting...
  50. ncbi Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia
    Elisa Lloyd-Smith
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    AIDS 20:445-50. 2006
    ..Members of the injection drug community, particularly those who are not taking HAART, experience elevated mortality in comparison with those without a history of drug use...
  51. ncbi Sexual risk profile of young men in Vancouver, British Columbia, who have sex with men and inject drugs
    Thomas M Lampinen
    The Vanguard Project: BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
    AIDS Behav 8:17-23. 2004
    ..Controlled assessments are needed to identify optimal sexual risk reduction strategies for MSM/IDU...
  52. ncbi "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy
    Evan Wood
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    J Acquir Immune Defic Syndr 30:159-66. 2002
    ..Similarities between transient and full virologic responders also appear to be time limited and are often associated with greater cumulative use of antiretroviral therapy by transient virologic responders...
  53. ncbi Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, British Columbia, Canada
    J Infect Dis 198:51-8. 2008
    ..We explore the temporal and regimen-specific changes of HIV-1 drug resistance in a large cohort of antiretroviral-naive individuals starting highly active antiretroviral therapy (HAART)...
  54. ncbi Marijuana and chronic obstructive lung disease: a population-based study
    Wan C Tan
    iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul s Hospital and the University of British Columbia, Vancouver, Canada
    CMAJ 180:814-20. 2009
    ..Our aim was to determine the combined and independent effects of tobacco and marijuana smoking on respiratory symptoms and chronic obstructive pulmonary disease (COPD) in the general population...
  55. ncbi Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting
    Ruth Joy
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    J Acquir Immune Defic Syndr 47:500-5. 2008
    ....
  56. ncbi Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3
    Adrienne R Toulson
    BC Centre for Excellence in HIV/AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 192:1787-93. 2005
    ..A nadir CD4 cell count of 200-250 cells/mm(3) and the 11/25 viral genotype were found to be associated with a faster HAART reinitiation...
  57. ncbi Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada
    Lena Normén
    Canadian HIV Trials Network, Pacific Region, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Nutr 135:820-5. 2005
    ..The results should stimulate further research to identify to what extent hunger-associated factors are reversible with interventions built on nutritional and/or social strategies...
  58. ncbi Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare
    Christine Tapp
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, and Department of Medicine, University of British Columbia, Vancouver, Canada
    BMC Infect Dis 11:86. 2011
    ..We evaluated access and adherence to ART in a long-term cohort of HIV-positive IDU in a setting where medical care and antiretroviral therapy are provided free of charge through a universal healthcare system...
  59. ncbi "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS ONE 6:e17402. 2011
    ..Virtual' or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values...
  60. ncbi Validity of self-reported adherence among injection drug users
    Thomas Kerr
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    J Int Assoc Physicians AIDS Care (Chic) 7:157-9. 2008
    ....
  61. ncbi The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 608 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    J Acquir Immune Defic Syndr 50:529-36. 2009
    ..To characterize the impact of longitudinal adherence on survival in drug-naive individuals starting currently recommended highly active antiretroviral therapy (HAART) regimens...
  62. ncbi Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART
    Sarah J Fielden
    B C Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada, Department of Interdisciplinary Studies, University of British Columbia, Vancouver, British Columbia, Canada
    J Int Assoc Physicians AIDS Care (Chic) 7:238-44. 2008
    ..Methods: Analysis was based on a cohort of individuals initiating HAART between 1996 and 2001. The primary outcome was hospitalization for one or more days. Survival methods were used to assess the impact of adherence on hospitalization...
  63. ncbi Prevalence of activity limitation among persons living with HIV/AIDS in British Columbia
    Melanie Rusch
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, and University of British Columbia, Vancouver, BC
    Can J Public Health 95:437-40. 2004
    ..Little research has examined the types and levels of activity limitations among HIV-positive populations. The objective of this report is to compare the levels of limitations among HIV-positive persons to the general population...
  64. ncbi Drug and HIV-related risk behaviors after geographic migration among a cohort of injection drug users
    Beth S Rachlis
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada, V6Z 1Y6
    AIDS Behav 14:854-61. 2010
    ..Our findings suggest that, in this setting, risk-taking among IDU declines following periods of migration out of Greater Vancouver...
  65. ncbi Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy
    Nelson Lee
    British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    J Infect Dis 188:137-41. 2003
    ..Over the short-term, patients receiving MDRT had relatively low mortality. After adjustment for baseline prognostic factors, rates of survival were comparable with those in patients initiating triple-drug ART...
  66. ncbi The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users
    Thomas Kerr
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    J Acquir Immune Defic Syndr 41:119-23. 2006
    ..We evaluated the HIV status of the sex partners of injection drug users (IDUs) and rates of subsequent HIV seroconversion among a prospective cohort study of IDUs...
  67. ncbi Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    Antivir Ther 9:229-35. 2004
    ....
  68. ncbi Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users
    Trevor A Corneil
    Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 608 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    Health Place 12:79-85. 2006
    ..Implications for policy including more comprehensive housing interventions (e.g. 'floating support') are discussed...
  69. ncbi Inability to access addiction treatment and risk of HIV infection among injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver and Department of Health Care and Epidemiology Faculty of Medicine, University of British Columbia, Canada
    J Acquir Immune Defic Syndr 36:750-4. 2004
    ....
  70. ncbi Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up
    Robert S Hogg
    Division of Epidemiology and Population Health, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    AIDS 16:1051-8. 2002
    ..97 times (95% CI, 1.33-6.62; P = 0.008) more likely to die. CONCLUSION: Our study demonstrates that even after adjusting for other prognostic factors intermittent use of antiretroviral therapy was associated with increased mortality...
  71. ncbi No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
    AIDS 16:1929-33. 2002
    ..1). CONCLUSION: GBV-C viremia is relatively common in individuals seeking treatment for HIV infection; however, it does not appear to have any effect on initial antiretroviral therapy response...
  72. ncbi Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program
    Paula Braitstein
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    J Infect Dis 193:259-68. 2006
    ..We sought to characterize the impact that hepatitis C virus (HCV) infection has on CD4 cells during the first 48 weeks of antiretroviral therapy (ART) in previously ART-naive human immunodeficiency virus (HIV)-infected patients...
  73. ncbi Prescribing practices in a population-based HIV postexposure prophylaxis program
    Paula Braitstein
    Division of Epidemiology and Population Health, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    AIDS 16:1067-70. 2002
    ..Receiving the remaining 23 days PEP was associated with being male, experiencing a community mucocutaneous or needlestick injury, and triple therapy as the initial 5 day starter PEP...
  74. ncbi When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients
    Evan Wood
    British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada
    Lancet Infect Dis 5:407-14. 2005
    ....
  75. ncbi Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy
    Katherine V Heath
    Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 31:211-7. 2002
    ..To estimate the frequency and possible predictors of patient-mediated intentional alterations in antiretroviral medication regimens in direct response to symptoms associated with antiretroviral therapy use...
  76. ncbi Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial
    Robert S Hogg
    BC Centre for Excellence in HIV/AIDS, University of British Columbia, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    J Acquir Immune Defic Syndr 31:521-8. 2002
    ..However, whether informing potential participants will reverse or contribute to the declining trend in WTP observed in this cohort warrants further investigation...
  77. ncbi Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use
    Anita Palepu
    Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 32:522-6. 2003
    ..07, 95% CI: 0.87-1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation...
  78. ncbi Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill
    Juan Delgado
    BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    Antivir Ther 8:471-8. 2003
    ....
  79. ncbi Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy
    Shayesta Dhalla
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    Complement Ther Clin Pract 12:242-8. 2006
    ..45). CAM use is common. Both patients and health professionals should be aware of potential toxicities and drug interactions related to the use of CAM and HIV/AIDS treatment...
  80. ncbi Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role
    Melanie Rusch
    University of British Columbia, Department of Health Care and Epidemiology, and the BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    Sex Transm Dis 31:492-8. 2004
    ..CONCLUSION: Type of drug use measure, partner, and role are important determinants of the association of specific substances and UAI...
  81. ncbi The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes
    Lily W Y Tam
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 49:266-71. 2008
    ....
  82. ncbi Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L
    Evan Wood
    St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
    Ann Intern Med 139:810-6. 2003
    ..Above a CD4+ cell count of 0.200 x 10(9) cells/L, medication adherence is the critical determinant of survival, not the CD4+ cell count at which HAART is begun...
  83. ncbi Similar sexual behaviors with casual partners among gay men with and without a regular partner
    Laura M Kuyper
    British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada
    Sex Transm Dis 32:203-5. 2005
    ..CONCLUSIONS: In our cohort, young gay men in a relationship do not appear less likely to engage in risky sex with casual partners than men with casual partners only...
  84. ncbi Regional and temporal trends in migration among people living with HIV/AIDS in British Columbia, 1993-2005
    Viviane D Lima
    HIV AIDS Drug Treatment Program, BC Centre for Excellence in HIV AIDS, 608 1081 Burrard Street, Vancouver, BC V6Z 1Y6
    Can J Public Health 101:44-9. 2010
    ..To examine regional and temporal trends in migration among patients receiving HIV treatment in British Columbia (BC)...
  85. ncbi Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine
    Thomas M Lampinen
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC
    CMAJ 172:479-83. 2005
    ..We evaluated the sexual behaviour of Canadian men who have sex with men (MSM) who participated in the phase III Vax004 trial of an HIV-1 vaccine...
  86. ncbi Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000
    Paula Braitstein
    British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    AIDS 17:2071-5. 2003
    ..CONCLUSIONS: The rate of ICP among HIV-positive individuals on ART appears to be increasing; in addition, the duration of time on ART is independently associated with ICP after adjustment for patient demographic characteristics...
  87. ncbi Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 55:460-5. 2010
    ..To model the effect of adherence and duration of viral suppression on the risk of viral rebound...